Spontaneous improvement of untreated mild Graves' ophthalmopathy: Rundle's curve revisited.

scientific article published on 09 December 2013

Spontaneous improvement of untreated mild Graves' ophthalmopathy: Rundle's curve revisited. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1089/THY.2013.0240
P8608Fatcat IDrelease_ptbfk3rbhndm7e6nxg2yf2kuua
P932PMC publication ID3887427
P698PubMed publication ID23980907

P50authorFrancesco LatrofaQ41657299
Marco NardiQ57628989
Maria Antonietta ProfiloQ61054438
P2093author name stringClaudio Marcocci
Francesca Menconi
Paolo Vitti
Michele Marinò
Roberto Rocchi
Marenza Leo
Eleonora Sisti
Maria Antonietta Altea
P2860cites workEffects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoidsQ79771160
Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomyQ82104621
Selenium and the course of mild Graves' orbitopathyQ28238021
Graves' ophthalmopathyQ28274196
Management of Graves' ophthalmopathy: reality and perspectivesQ33899550
Natural history of thyroid associated ophthalmopathyQ34059445
Rundle and his curveQ34170719
Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigensQ35215882
Immunosuppressive treatment of Graves' ophthalmopathyQ35469963
Graves' ophthalmopathy: state of the art and perspectivesQ35785171
Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathyQ37110191
Clinical practice. Graves' ophthalmopathyQ37407540
Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy.Q37751763
Treatment of mild, moderate-to-severe and very severe Graves' orbitopathyQ38013216
Thyroid volume and severity of Graves' orbitopathyQ43745434
Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidismQ43907362
A treatment strategy for Graves' orbitopathyQ44252754
Natural history of thyroid eye diseaseQ47759032
Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial.Q48560620
Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.Q50933902
Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.Q51258119
Occurrence of Ophthalmopathy after Treatment for Graves' HyperthyroidismQ57482592
Modification of the Classification of the Eye Changes of Graves' Disease: Recommendations of the Ad Hoc Committee of The American Thyroid AssociationQ67020629
Ophthalmic Graves's disease: natural history and detailed thyroid function studiesQ67020768
Prevalence, natural history and surgical treatment of exophthalmosQ69395891
Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?Q72414211
Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathyQ74010201
Management of exophthalmos and related ocular changes in Graves' diseaseQ74338185
Graves' ophthalmopathy: natural history and treatment outcomesQ77575202
P433issue1
P304page(s)60-66
P577publication date2013-12-09
P1433published inThyroidQ15709940
P1476titleSpontaneous improvement of untreated mild Graves' ophthalmopathy: Rundle's curve revisited
P478volume24

Reverse relations

cites work (P2860)
Q53192241Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves' orbitopathy (GO): a new frontier for GO treatment?
Q38784922Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.
Q91842643Analysis of Foveal and Parafoveal Microvascular Density and Retinal Vessel Caliber Alteration in Inactive Graves' Ophthalmopathy
Q89680367Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves' orbitopathy (GO)
Q52715564Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy.
Q101166513Clinical features and clinical course of thyroid-associated ophthalmopathy: a case series of 3620 Chinese cases
Q42667849Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question
Q26782424Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management
Q89868242Intraorbital Steroid Injection for Active Thyroid Ophthalmopathy
Q86549348Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy
Q37616156Methotrexate for the treatment of thyroid eye disease
Q38963406Natural course of mild Graves' orbitopathy: is it a chronic remitting or a transient disease?
Q48318128Natural history of graves' orbitopathy after treatment.
Q64248548Orbital Radiotherapy Plus Concomitant Steroids in Moderate-to-Severe Graves' Ophthalmopathy: Good Results After Long-Term Follow-Up
Q35055124Randomized controlled trial of rituximab in patients with Graves' orbitopathy
Q26749195THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathy
Q55140443Thyroid-Associated Orbitopathy and Biomarkers: Where We Are and What We Can Hope for the Future.
Q38367695Total thyroid ablation in Graves' orbitopathy

Search more.